Join a 30-minute morning educational session led by Drs. Myung-Ju Ahn and Natasha Leighl on October 1st at 9 am KST! They’ll explore TROP2-directed ADCs in EGFR-mutated advanced NSCLC after TKI failure, with guidance on patient selection and toxicity management.

ESMO TAT Asia 2025 초록 모집 안내 (~4/29 마감) ESMO TAT (Targeted Anticancer Therapies) Asia Congress 2025 (7/18~7/20) 홍콩에서 개최됩니다. [ESMO Targeted Anticancer Therapies Asia Congress 2025 - Submit your abstract] piped.video/DENYodl8IFw?si=Wr0V…

RT @nuvalent: Today, we presented new preclinical #data supporting intracranial activity of NVL-655 at #AACR23. Thank you to our collaborat…

Repotrectinib data presented by @cbcbc1971 . #ena2022 #ROS1

On National Lung Cancer Screening Day, I would like to thank and support the efforts of Byoung Chul Cho @cbcbc1971 & his study -Novel drug for #LungCancer showing promise in early-stage clinical trials @marjoriezettler Learn how @qure_ai is working for the cause. #RSNA22

@cbcbc1971 nicely overviewed antibody-drug conjugates (ADCs), bispecific antibodies. T-DXd, Dato-DXd, HER3-DXd, Teliso-V, Amivantamab, and Tarlatamab, etc. #LCSM #TASLC

Today, we presented new preclinical #data supporting intracranial activity of NVL-655 at #AACR23. Thank you to our collaborators Dr. Cho @cbcbc1971 and his group at Yonsei University College of Medicine.

Looking forward to seeing you at #WCLC2021!! If anyone else is interested in Antibody–Drug Conjugates in #lungcancer, Please come to the education session ES04 at @WCLC2021 on Sep 10.